Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

August 10, 2019

Study Completion Date

August 10, 2019

Conditions
PTSD
Interventions
DRUG

Midomafetamine

80 to 120 mg MDMA

BEHAVIORAL

Manualized therapy

Non-directive therapy conducted during MDMA-assisted therapy session

Trial Locations (12)

10016

New York University, New York

10024

Affective Care, New York

29464

Zen Therapeutic Solutions, LLC, Mt. Pleasant

53705

University of Wisconsin at Madison, Madison

70123

Ray Worthy Psychiatry LLC, New Orleans

80302

Aguazul-Blue Water Inc., Boulder

80525

Wholeness Center, Fort Collins

91601

New School Research LLC, North Hollywood

94114

San Francisco Insight and Integration Center, San Francisco

94122

University of California San Francisco, San Francisco

06030

University of Connecticut, Farmington

02446

Trauma Research Foundation, Brookline

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Lykos Therapeutics

INDUSTRY